{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:40:15Z","timestamp":1792694415350,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T00:00:00Z","timestamp":1506038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00520-017-3854-x","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T05:53:41Z","timestamp":1506059621000},"page":"7-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["A systematic literature review of the efficacy, effectiveness, and safety of filgrastim"],"prefix":"10.1007","volume":"26","author":[{"given":"David C.","family":"Dale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zandra","family":"Klippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Osslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Khanh","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Allcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,22]]},"reference":[{"key":"3854_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/1097-0142(196606)19:6<781::AID-CNCR2820190607>3.0.CO;2-U","volume":"19","author":"GP Bodey","year":"1966","unstructured":"Bodey GP, Powell RD Jr, Hersh EM, Yeterian A, Freireich EJ (1966) Pulmonary complications of acute leukemia. Cancer 19:781\u2013793","journal-title":"Cancer"},{"key":"3854_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw 6:109\u2013118","journal-title":"J Natl Compr Cancer Netw"},{"key":"3854_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228\u2013237","journal-title":"Cancer"},{"key":"3854_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164\u2013170","journal-title":"N Engl J Med"},{"key":"3854_CR5","first-page":"187","volume":"4","author":"DC Dale","year":"2006","unstructured":"Dale DC (2006) Update on the management of neutropenia. Clin Adv Hematol Oncol 4:187\u2013189","journal-title":"Clin Adv Hematol Oncol"},{"key":"3854_CR6","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood.V81.10.2496.2496","volume":"81","author":"DC Dale","year":"1993","unstructured":"Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J et al (1993) A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81:2496\u20132502","journal-title":"Blood"},{"issue":"Suppl 1","key":"3854_CR7","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0959-8049(99)00259-2","volume":"36","author":"J Chang","year":"2000","unstructured":"Chang J (2000) Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36(Suppl 1):S11\u2013S14","journal-title":"Eur J Cancer"},{"key":"3854_CR8","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","volume":"21","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524\u20134531","journal-title":"J Clin Oncol"},{"key":"3854_CR9","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood.V84.9.2923.2923","volume":"84","author":"GS Chatta","year":"1994","unstructured":"Chatta GS, Price TH, Allen RC, Dale DC (1994) Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 84:2923\u20132929","journal-title":"Blood"},{"key":"3854_CR10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V88.1.335.335","volume":"88","author":"TH Price","year":"1996","unstructured":"Price TH, Chatta GS, Dale DC (1996) Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 88:335\u2013340","journal-title":"Blood"},{"key":"3854_CR11","unstructured":"NEUPOGEN\u00ae (filgrastim) [prescribing information]: Thousand Oaks, CA: Amgen Inc."},{"key":"3854_CR12","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"key":"3854_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404","journal-title":"BMC Cancer"},{"key":"3854_CR14","volume":"10","author":"P Renner","year":"2012","unstructured":"Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M (2012) Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev 10:CD007913","journal-title":"Cochrane Database Syst Rev"},{"key":"3854_CR15","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","volume":"18","author":"D Sheppard","year":"2012","unstructured":"Sheppard D, Bredeson C, Allan D, Tay J (2012) Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant 18:1191\u20131203","journal-title":"Biol Blood Marrow Transplant"},{"key":"3854_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"3854_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N (2015) Meta-analysis in clinical trials revisited. Contemp Clin Trials 45:139\u2013145","journal-title":"Contemp Clin Trials"},{"key":"3854_CR18","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.3747\/co.20.1306","volume":"20","author":"AK Altwairgi","year":"2013","unstructured":"Altwairgi AK, Hopman WM, Mates M (2013) Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol 20:e171\u2013e179","journal-title":"Curr Oncol"},{"issue":"suppl 9","key":"3854_CR19","doi-asserted-by":"publisher","first-page":"ix499","DOI":"10.1093\/annonc\/mds416","volume":"23","author":"M He","year":"2012","unstructured":"He M, Huang S, Yu L, Shi G, Deng J, Zhang X et al (2012) Evaluation of the quality of life and economic burden with granulocyte-colony stimulating factor in Chinese breast cancer patients receiving docetaxel, epirubicin and cyclophosphamide. Ann Oncol 23(suppl 9):ix499\u2013ix527. https:\/\/doi.org\/10.1093\/annonc\/mds416 . This article appears in: Abstract Book of the 37th ESMO Congress Vienna, Austria, 28 September\u20132 October 2012","journal-title":"Ann Oncol"},{"key":"3854_CR20","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1200\/JCO.2003.03.034","volume":"21","author":"P Papaldo","year":"2003","unstructured":"Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E et al (2003) Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 21:3462\u20133468","journal-title":"J Clin Oncol"},{"key":"3854_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/1471-2407-8-332","volume":"8","author":"A Giglio del","year":"2008","unstructured":"del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel\/doxorubicin chemotherapy. BMC Cancer 8:332","journal-title":"BMC Cancer"},{"key":"3854_CR22","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1073\/pnas.82.5.1526","volume":"82","author":"K Welte","year":"1985","unstructured":"Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R et al (1985) Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A 82:1526\u20131530","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3854_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","volume":"29A","author":"V Trillet-Lenoir","year":"1993","unstructured":"Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319\u2013324","journal-title":"Eur J Cancer"},{"key":"3854_CR24","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.1998.16.2.716","volume":"16","author":"SD Fossa","year":"1998","unstructured":"Fossa SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I et al (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716\u2013724","journal-title":"J Clin Oncol"},{"key":"3854_CR25","first-page":"3974","volume":"89","author":"PL Zinzani","year":"1997","unstructured":"Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L et al (1997) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin\u2019s lymphoma. Blood 89:3974\u20133979","journal-title":"Blood"},{"key":"3854_CR26","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1200\/JCO.2003.01.076","volume":"21","author":"JK Doorduijn","year":"2003","unstructured":"Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH et al (2003) CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 21:3041\u20133050","journal-title":"J Clin Oncol"},{"key":"3854_CR27","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1182\/blood-2002-10-3238","volume":"101","author":"E Osby","year":"2003","unstructured":"Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E et al (2003) CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 101:3840\u20133848","journal-title":"Blood"},{"key":"3854_CR28","first-page":"1556","volume":"92","author":"RA Larson","year":"1998","unstructured":"Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ et al (1998) A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92:1556\u20131564","journal-title":"Blood"},{"key":"3854_CR29","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJM199706193362503","volume":"336","author":"CH Pui","year":"1997","unstructured":"Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT et al (1997) Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336:1781\u20131787","journal-title":"N Engl J Med"},{"key":"3854_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1634\/theoncologist.10-2-138","volume":"10","author":"DW Blayney","year":"2005","unstructured":"Blayney DW, McGuire BW, Cruickshank SE, Johnson DH (2005) Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin\u2019s lymphoma. Oncologist 10:138\u2013149","journal-title":"Oncologist"},{"key":"3854_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s005200050258","volume":"7","author":"J Gilad","year":"1999","unstructured":"Gilad J, Riesenberg K, Mermershtain W, Borer A, Porath A, Schlaeffer F (1999) Granulocyte-colony stimulating factor for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of Southern Israel. Support Care Cancer 7:260\u2013264","journal-title":"Support Care Cancer"},{"key":"3854_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3111\/13696990903238603","volume":"12","author":"D Hershman","year":"2009","unstructured":"Hershman D, Hurley D, Wong M, Morrison VA, Malin JL (2009) Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ 12:203\u2013210","journal-title":"J Med Econ"},{"key":"3854_CR33","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","volume":"90","author":"G Heil","year":"1997","unstructured":"Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 90:4710\u20134718","journal-title":"Blood"},{"key":"3854_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.leukres.2010.07.005","volume":"35","author":"M Beksac","year":"2011","unstructured":"Beksac M, Ali R, Ozcelik T, Ozcan M, Ozcebe O, Bayik M et al (2011) Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial. Leuk Res 35:340\u2013345","journal-title":"Leuk Res"},{"key":"3854_CR35","doi-asserted-by":"crossref","unstructured":"Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE et al (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 91:3607\u20133615","DOI":"10.1182\/blood.V91.10.3607"},{"key":"3854_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1365-2141.2002.03251.x","volume":"116","author":"K Usuki","year":"2002","unstructured":"Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N et al (2002) Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 116:103\u2013112","journal-title":"Br J Haematol"},{"key":"3854_CR37","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2000.18.4.780","volume":"18","author":"JL Harousseau","year":"2000","unstructured":"Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M et al (2000) Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 18:780\u2013787","journal-title":"J Clin Oncol"},{"key":"3854_CR38","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V89.3.780","volume":"89","author":"JO Moore","year":"1997","unstructured":"Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B et al (1997) Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood 89:780\u2013788","journal-title":"Blood"},{"key":"3854_CR39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/sj.leu.2404090","volume":"20","author":"G Heil","year":"2006","unstructured":"Heil G, Hoelzer D, Sanz MA, Lechner K, Noens L, Szer J et al (2006) Long-term survival data from a phase 3 study of filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia 20:404\u2013409","journal-title":"Leukemia"},{"key":"3854_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/MPH.0b013e3180f61b26","volume":"29","author":"D Yilmaz","year":"2007","unstructured":"Yilmaz D, Ritchey AK (2007) Severe neutropenia in children: a single institutional experience. J Pediatr Hematol Oncol 29:513\u2013518","journal-title":"J Pediatr Hematol Oncol"},{"key":"3854_CR41","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/sj.bmt.1704699","volume":"34","author":"M Gonzalez-Vicent","year":"2004","unstructured":"Gonzalez-Vicent M, Madero L, Sevilla J, Ramirez M, Diaz MA (2004) A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplant 34:1077\u20131081","journal-title":"Bone Marrow Transplant"},{"key":"3854_CR42","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/bmt.2010.233","volume":"46","author":"MA Gertz","year":"2011","unstructured":"Gertz MA, Gastineau DA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK et al (2011) SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplant 46:956\u2013961","journal-title":"Bone Marrow Transplant"},{"key":"3854_CR43","first-page":"261","volume":"15","author":"N Schmitz","year":"1995","unstructured":"Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA et al (1995) Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 15:261\u2013266","journal-title":"Bone Marrow Transplant"},{"key":"3854_CR44","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1200\/JCO.1994.12.9.1931","volume":"12","author":"RA Stahel","year":"1994","unstructured":"Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A et al (1994) Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 12:1931\u20131938","journal-title":"J Clin Oncol"},{"key":"3854_CR45","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/annonc\/mdv174","volume":"26","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Reiner M, Morrow PK, Crawford J (2015) The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol 26:1452\u20131458","journal-title":"Ann Oncol"},{"key":"3854_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","volume":"77","author":"H Wildiers","year":"2011","unstructured":"Wildiers H, Reiser M (2011) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 77:221\u2013240","journal-title":"Crit Rev Oncol Hematol"},{"key":"3854_CR47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/COC.0000000000000141","volume":"37","author":"L Balducci","year":"2014","unstructured":"Balducci L, Mo M, Abella E, Saven A (2014) Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim. Am J Clin Oncol 37:603\u2013610","journal-title":"Am J Clin Oncol"},{"key":"3854_CR48","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.6004\/jnccn.2015.0166","volume":"13","author":"N Denduluri","year":"2015","unstructured":"Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM et al (2015) Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr Cancer Netw 13:1383\u20131393","journal-title":"J Natl Compr Cancer Netw"},{"key":"3854_CR49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","volume":"93","author":"LJ Havrilesky","year":"2015","unstructured":"Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J (2015) A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol 93:203\u2013210","journal-title":"Crit Rev Oncol Hematol"},{"key":"3854_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ajh.10255","volume":"72","author":"DC Dale","year":"2003","unstructured":"Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA et al (2003) Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 72:82\u201393","journal-title":"Am J Hematol"},{"key":"3854_CR51","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4172\/2157-7633.1000214","volume":"4","author":"WYK Hwang","year":"2014","unstructured":"Hwang WYK, Poon Z, Bari S (2014) Improving the efficacy and availability of stem cell transplant therapies for hematopoietic stem cell transplantation. J Stem Cell Res Ther 4:214. https:\/\/doi.org\/10.4172\/2157-7633.1000214","journal-title":"J Stem Cell Res Ther"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3854-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3854-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3854-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T03:16:52Z","timestamp":1602991012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3854-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,22]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3854"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3854-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,22]]},"assertion":[{"value":"8 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"David Dale has received research support from and is a consultant for Amgen Inc. Jeffrey Crawford has received research support from Amgen Inc., AstraZeneca, Bayer, Clovis, and GTx; has been a scientific advisor for Merck, Novartis, and Pfizer; and has participated as a member of a data and safety monitoring board for Celgene, G1 Therapeutics, Janssen, Merrimack, and Roche. Zandra Klippel, Maureen Reiner, Timothy Osslund, Ellen Fan, and Phuong Khanh Morrow are employees of and own stock in Amgen Inc. Kim Allcott is an employee of Oxford PharmaGenesis Ltd., which has received project funding from Amgen Inc. and Amgen (Europe) GmbH. Gary Lyman has received research support from Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Formal consent was not required, as the article does not contain any studies involving human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}